Compare HIMX & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HIMX | ATAI |
|---|---|---|
| Founded | 2001 | 2018 |
| Country | Taiwan | United States |
| Employees | N/A | 54 |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.3B |
| IPO Year | 2006 | 2021 |
| Metric | HIMX | ATAI |
|---|---|---|
| Price | $9.80 | $3.75 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $15.57 |
| AVG Volume (30 Days) | 2.6M | ★ 4.6M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 3.65% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $308,000.00 |
| Revenue This Year | $14.94 | N/A |
| Revenue Next Year | $7.79 | $285.00 |
| P/E Ratio | $14.99 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.66 | $1.15 |
| 52 Week High | $12.00 | $6.73 |
| Indicator | HIMX | ATAI |
|---|---|---|
| Relative Strength Index (RSI) | 72.70 | 46.97 |
| Support Level | $8.24 | $3.41 |
| Resistance Level | N/A | $4.40 |
| Average True Range (ATR) | 0.57 | 0.26 |
| MACD | 0.30 | 0.01 |
| Stochastic Oscillator | 56.93 | 31.70 |
Himax Technologies Inc is a semiconductor solution provider dedicated to display imaging processing technologies. It operates through the Driver Integrated Circuit and Non-Driver Products segments. The majority of the firm's revenue is derived from the Driver Integrated Circuit segment. It offers display driver ICs and timing controllers used in TVs, laptops, monitors, mobile phones, tablets, digital cameras, virtual reality (VR) devices, and many other consumer electronics devices. It also designs and provides controllers for touch sensor displays, in-cell Touch and Display Driver Integration single-chip solutions, LED driver ICs, power management ICs, and scaler products for monitors and projectors. Geographically, it generates the majority of its revenue from China.
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.